Mayne Pharma Group Ltd
ASX:MYX
Mayne Pharma Group Ltd
ASX:MYX
Price:
7.12 AUD
-0.28%
Market Closed
Updated:
May 10, 2024
Mayne Pharma Group Ltd
Cost of Revenue
|
Mayne Pharma Group Ltd
Cost of Revenue Peer Comparison
Comparables:
RCE
NEU
BOT
PBP
C
CU6
Competitive Cost of Revenue Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Cost of Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
Mayne Pharma Group Ltd
ASX:MYX
|
Cost of Revenue
-AU$99.9m
|
CAGR 3-Years
26%
|
CAGR 5-Years
16%
|
CAGR 10-Years
N/A
|
|
|
Recce Pharmaceuticals Ltd
ASX:RCE
|
Cost of Revenue
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Neuren Pharmaceuticals Ltd
ASX:NEU
|
Cost of Revenue
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Botanix Pharmaceuticals Ltd
ASX:BOT
|
Cost of Revenue
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Probiotec Ltd
ASX:PBP
|
Cost of Revenue
-AU$155m
|
CAGR 3-Years
-28%
|
CAGR 5-Years
-26%
|
CAGR 10-Years
-15%
|
|
C
|
Clarity Pharmaceuticals Ltd
ASX:CU6
|
Cost of Revenue
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
See Also
What is Mayne Pharma Group Ltd's Cost of Revenue?
Cost of Revenue
-99.9m
AUD
-99.9m
AUD
Based on the financial report for Jun 30, 2023, Mayne Pharma Group Ltd's Cost of Revenue amounts to -99.9m AUD.
What is Mayne Pharma Group Ltd's Cost of Revenue growth rate?
Cost of Revenue CAGR 5Y
16%
16%
Over the last year, the Cost of Revenue growth was -21%. The average annual Cost of Revenue growth rates for Mayne Pharma Group Ltd have been 26% over the past three years , 16% over the past five years .
You don't have any saved screeners yet
